The global celiac disease drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Celiac disease is an autoimmune disorder in which a protein called gluten damages the small intestine's membrane. Gluten can be present in grains such as rye, barley, and wheat. Gluten causes an immunological reaction that damages the villi in the small intestine (small finger-like projections in the small intestine which promote absorption). The body's ability to absorb proteins, nutrients, lipids, vitamins, carbs, and minerals is hampered by the damage. This eventually leads to malnutrition. It causes neurological malfunction, infertility, osteoporosis, and anemia if left untreated. Men and women of various ages and races are affected by celiac disease. HLA DQ2 and HLA DQ8 are two of the most critical genes linked to celiac disease. About 30% of the world's population carries one or both genes, however, only one in every 30 people will acquire the condition. Screening and biopsy are used to diagnose the condition. It is estimated that 80% of celiac disease cases go undetected or are misdiagnosed as another disease.
The key players operating in the global celiac disease drug market include Pfizer Inc., Johnson & Johnson Services, Inc., and Bristol-Myers Squibb Co., among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in August 2020, Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease announced the initiation of the Phase 2b PROACTIVE (PROvention Amgen Celiac ProtecTIVE) study of PRV-015, an anti-interleukin-15 monoclonal antibody, in adult celiac patients not responding to a gluten-free diet, a condition known as 'Non-Responsive Celiac Disease' (NRCD). Moreover, in November 2019, Bristol-Myers Squibb Co., has announced the acquisition of Celgene Corporation, a company that works in celiac disease treatment. This acquisition expands the product portfolio for Bristol company.
Market Coverage
Segment Covered-
Regions Covered-
Competitive Landscape- Pfizer Inc., Johnson & Johnson Services, Inc., and Bristol-Myers Squibb Co., among others.
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Celiac Disease Drug Market Report by Segment
By Drugs
Global Celiac Disease Drug Market Report by Region
North America
Europe
Asia-Pacific
Rest of the World